Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LABORATORY CORPORATION OF AMERICA HOLDINGS

(LH)
  Report
Delayed Nyse  -  04:00 2022-09-26 pm EDT
210.43 USD   -0.58%
09/21Magna Mining Provides Operations Update
MT
09/19Argus Downgrades Laboratory Corp. of America Holdings to Hold From Buy
MT
09/13Transcript : Laboratory Corporation of America Holdings Presents at Baird 2022 Global Healthcare Conference, Sep-13-2022 09:05 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Becton, Dickinson and Company, Labcorp Collaborate to Develop Flow Cytometry-Based Companion Diagnostics for Matching Patients with Treatments

08/09/2022 | 06:50am EDT

Becton, Dickinson and Company announced a collaboration agreement with Labcorp creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics intended to match patients with life-changing treatments for cancer and other diseases. The agreement creates a framework for BD and Labcorp Drug Development to collaborate on flow cytometry-based CDx opportunities with pharmaceutical partners. The two companies bring together capabilities that comprise an end-to-end solution for CDx development for the pharmaceutical industry.

Their joint offering ranges from exploratory panel development to U.S. Food and Drug Administration approval of diagnostic and IVD kit manufacturing and distribution. Selecting the optimal first-line therapy for patients with cancer by using companion diagnostics can be critical to ensuring the best outcomes and time and cost savings. Today's companion diagnostic tests commonly involve technologies such as immunohistochemistry, fluorescence in situ hybridization, polymerase chain reaction, next-generation sequencing and imaging.

Flow cytometry is an emerging technology in the field.


© S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
BECTON, DICKINSON AND COMPANY -0.97% 231.64 Delayed Quote.-4.82%
LABORATORY CORPORATION OF AMERICA HOLDINGS -0.58% 210.43 Delayed Quote.-33.03%
All news about LABORATORY CORPORATION OF AMERICA HOLDINGS
09/21Magna Mining Provides Operations Update
MT
09/19Argus Downgrades Laboratory Corp. of America Holdings to Hold From Buy
MT
09/13Transcript : Laboratory Corporation of America Holdings Presents at Baird 202..
CI
09/06Laboratory Corp Of America Holdings : Regulation FD Disclosure (form 8-K)
AQ
09/06Laboratory Of America : at the Baird 2022 Global Healthcare Conference
PU
09/06Labcorp to Speak at the Baird 2022 Global Healthcare Conference
BU
08/31Testing, Treatment, and Vaccines are the Three Ways Companies Can Fight Monkeypox (SKHH..
AQ
08/23Laboratory Corp of America Closes Acquisition of RWJBarnabas Health's Outreach Lab Busi..
MT
08/23Labcorp Acquires Clinical Outreach Laboratory Services From RWJBarnabas Health
BU
08/23North American Morning Briefing: Stock Futures -2-
DJ
More news
Analyst Recommendations on LABORATORY CORPORATION OF AMERICA HOLDINGS
More recommendations
Financials (USD)
Sales 2022 15 236 M - -
Net income 2022 1 610 M - -
Net Debt 2022 3 824 M - -
P/E ratio 2022 12,3x
Yield 2022 0,65%
Capitalization 19 023 M 19 023 M -
EV / Sales 2022 1,50x
EV / Sales 2023 1,47x
Nbr of Employees 71 725
Free-Float 99,7%
Chart LABORATORY CORPORATION OF AMERICA HOLDINGS
Duration : Period :
Laboratory Corporation of America Holdings Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LABORATORY CORPORATION OF AMERICA HOLDINGS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 210,43 $
Average target price 299,92 $
Spread / Average Target 42,5%
EPS Revisions
Managers and Directors
Adam H. Schechter Chairman, President & Chief Executive Officer
Glenn Andrew Eisenberg Chief Financial Officer & Executive Vice President
Lance V. Berberian Chief Information & Technology Officer & EVP
Brian J. Caveney Chief Medical Officer, EVP & President-Diagnostics
Stephen M. Anderson Chief Scientific Officer-Covance & Senior VP
Sector and Competitors